Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment Publication underscores the importance of data in underrecognized neuropat

7 Steps to Investing in Marijuana Stocks

06:49pm, Friday, 16'th Dec 2022 The Motley Fool
Here are seven steps to investing in the high-flying cannabis industry.

Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

10:35pm, Monday, 07'th Nov 2022 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Murphy - Manager, Investor Relations Christopher Posner - President, CE
Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cara Therapeutics to Present at Upcoming Investor Conferences

11:00am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pati
STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Cara (CARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pati
STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
The mean of analysts' price targets for Cara (CARA) points to a 132.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

11:00am, Monday, 12'th Sep 2022 GlobeNewswire Inc.
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) –
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE